Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma

详细信息    查看全文

• 作者：Yin-Hsun Feng (1) (2)
  Cheng-Yao Lin (3)
  Wen-Tsung Huang (3)
  Chia-Ling Wu (3)
  Jui-Lung Fang (4)
  Chao-Jung Tsao (3)
  
• 关键词：Diabetes mellitus ; Hepatocellular carcinoma ; Insulin ; Intra ; arterial chemotherapy
• 刊名：Medical Oncology
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：28
• 期：4
• 页码：1080-1088
• 全文大小：298KB
• 参考文献：1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-3. CrossRef
  2. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009.
  3. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11(47):7391-00.
  4. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets. 2005;5(2):131-. CrossRef
  5. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2008;14(42):6437-1. CrossRef
  6. Lai EC, et al. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer. 1990;66(8):1685-. CrossRef
  7. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11(7):790-00. CrossRef
  8. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969-7.
  9. Murata K, et al. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unrespectable hepatocellular carcinoma. Anticancer Res. 2003;23(2C):1719-2.
  10. Ando E, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588-5. CrossRef
  11. Tanioka H, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res. 2003;23(2C):1891-.
  12. Kingston ME, Ali MA, Atiyeh M, Donnelly RJ. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology. 1984;87(3):688-4.
  13. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer. 1997;73(2):204-. CrossRef
  14. Tazawa J, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci. 2002;47(4):710-. CrossRef
  15. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43(6):1295-02. CrossRef
  16. Caudle AS, et al. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol. 2008;15(7):1931-. CrossRef
  17. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997; 20(7):1183-197.
  18. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000;92(3):205-6. CrossRef
  19. Link KH, et al. In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol. 1998;14(3):189-01. CrossRef
  20. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-0. CrossRef
  21. Sakai K, Clemmons DR. Glucosamine induces resistance to insulin-like growth factor I (IGF-I) and insulin in Hep G2 cell cultures: biological significance of IGF-I/insulin hybrid receptors. Endocrinology. 2003;144(6):2388-5. CrossRef
  22. Miglietta A, et al. Insulin can modulate MCF-7 cell response to paclitaxel. Cancer Lett. 2004;209(2):139-5. CrossRef
  23. Sasaki A. Mortality and causes of death in patients with diabetes mellitus in Japan. Diabetes Res Clin Pract. 1994;24(Suppl):S299-06. CrossRef
  24. Adami HO, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88(20):1472-. CrossRef
  25. Hassan MM, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36(5):1206-3. CrossRef
  26. Chen CL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111-1. CrossRef
  27. Komura T, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol. 2007;102(9):1939-6. CrossRef
  28. Kawamura Y, et al. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol. 2008;23(11):1739-6. CrossRef
  29. Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-4. CrossRef
  30. Yamasaki T, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol. 2005;40(1):70-. CrossRef
  31. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831-4. CrossRef
  32. Moriya K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4(9):1065-. CrossRef
  33. Yoneda M, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat. 2007;14(9):600-. CrossRef
  34. Ding XZ, et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21(3):310-0. CrossRef
  35. Fisher WE, Boros LG, Schirmer WJ. Reversal of enhanced pancreatic cancer growth in diabetes by insulin. Surgery. 1995;118(2):453-. (discussion 7-). CrossRef
  36. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25(27):3787-00. CrossRef
  37. Fu XX, et al. Insulin like growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol. 1988;62(9):3422-0.
  38. Li D, et al. Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009.
  39. Takiya L, Chawla S. Therapeutic options for the management of type 2 diabetes mellitus. Am J Manag Care. 2002;8(11):1009-3. (quiz 24-).
  
• 作者单位：Yin-Hsun Feng (1) (2)
  Cheng-Yao Lin (3)
  Wen-Tsung Huang (3)
  Chia-Ling Wu (3)
  Jui-Lung Fang (4)
  Chao-Jung Tsao (3)
  
  1. Graduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 1, Ta-Hsueh Road, Tainan City, 70101, Taiwan
  2. Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, 901, Chung-Hwa Road, Yong Kang City, Tainan County, 71004, Taiwan
  3. Department of Hematology-Oncology, Chi-Mei Medical Center, Liouying, 201 Taikang Village, Liouying Township, Tainan County, 73657, Taiwan
  4. Department of Radiology, Chi-Mei Medical Center, Liouying, 201 Taikang Village, Liouying Township, Tainan County, 73657, Taiwan
  

文摘

Diabetes mellitus is associated with a poorer outcome in patients with hepatocellular carcinoma. The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain. Intra-arterial chemotherapy is one of the therapeutic options of unrespectable hepatocellular carcinoma. To clarify this point, we analyze the therapeutic effect of intra-arterial chemotherapy in unrespectable hepatocellular carcinoma patients with or without diabetes mellitus. Fifty-two patients with advanced hepatocellular carcinoma underwent intra-arterial chemotherapy with cisplatin and fluorouracil. Tumor response was assessed by computed tomography. An in vitro hepatocellular carcinoma cell line, Hep G2, was evaluated for the cytotoxic effect of cisplatin and fluorouracil in different concentrations of insulin and glucose mimicking diabetic conditions. Fifty-two patients were included, 14 had diabetes and 38 were non-diabetics. Non-diabetic patients had a lower rate of progressive disease (16% vs. 43%, P?=?0.039). The median time to progression was significantly longer in non-diabetics compared with the diabetic counterpart (a median of 206?days vs. 88?days, P?=?0.02). In the hepatocellular carcinoma cell line, Hep G2, insulin rather than glucose was more important for promoting cell proliferation and enhancing the drug resistance of cisplatin or fluorouracil. Our study showed that intra-arterial chemotherapy for unrespectable hepatocellular carcinoma was less effective in diabetic patients than the non-diabetic counterpart in terms of the progression-free rate and time to disease progression survival.